I am a pediatric oncologist who specializes in the treatment of children with neuroblastoma. With my colleagues, I am researching and developing innovative immunotherapies for this disease.
I have a strong research background in immunology that fuels my work both in the lab and with my patients. I am intrigued by the natural power of the immune system to fight disease. We have learned how to harness this power to recognize and fight cancer. Immunotherapies that were pioneered at Memorial Sloan Kettering are now part of the standard of care for children with neuroblastoma.
In my research, my colleagues and I are working to develop new approaches for treating neuroblastoma with antibodies. In one approach, some of a patient’s T cells (white blood cells) are removed and attached to a specific antibody which recognizes neuroblastoma cells. These modified T cells could then be returned to the patient, where they would recruit other T cells in the body to attack and kill neuroblastoma cells. We expect that this approach could be even more effective than the immunotherapies we use today. I hope my research can help bring new therapies into clinical trials and one day soon improve the survival of children with neuroblastoma.
The team of neuroblastoma experts at Memorial Sloan Kettering treats more patients with neuroblastoma than any other institution in the world. We have a shared enthusiasm for learning more about this disease and striving to improve the survival of our patients.
When I meet with the parents of a child with neuroblastoma, I listen carefully to what they have to say. Parents know their children better than anyone, and are vital partners in planning and carrying out a child’s treatment.
- Clinical Expertise: Pediatric Oncology; Neuroblastoma and other Neuroectodermal Tumors; Immunotherapy
- Languages Spoken: English
- Education: MD, Albert Einstein College of Medicine
- Residencies: Pediatrics - Children's Hospital Boston/Boston Medical Center
- Fellowships: Pedatric Hematology/Oncology - Children's Hospital Boston/Dana-Farber Cancer Institute
- Board Certifications: Pediatrics
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Ellen M. Basu
- A Phase I Study of Entrectinib in Children and Adolescents with Persistent or Recurrent Solid Tumors in the Body or Brain
- A Phase I Study of Humanized 3F8 Monoclonal Antibody in Patients with High-Risk Neuroblastoma and GD2-Positive Tumors
- A Pilot Phase II Study of Targeted Radiotherapy with 131I-MIBG and Arsenic Trioxide in Patients with Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors
Clinical Trials Co-Investigated by Ellen M. Basu
- A Phase I Study of Difluoromethylornithine and Celecoxib with Cyclophosphamide and Topotecan in Patients with Recurrent or Persistent Neuroblastoma
- A Phase I Study of Hu3F8 with Donated Natural Killer Cells to Treat Recurrent or Persistent Neuroblastoma
- A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan for Recurrent or Persistent Neuroblastoma
- A Phase II Study of Iodine 131-MIBG Alone and with Other Anticancer Drugs in Patients with Recurrent or Persistent Neuroblastoma